Letter to the Editor
Preferential location of circulating activated cyclophosphamide within the erythrocyte
First published: 1 March 1996
No abstract is available for this article.
References
-
Belfayol, L.,
Guillevin, L.,
Louchahi, K.,
Lortholary, O.,
Bosio, A. M. and
Fauvelle, F.,
Measurement of 4-Hydroxycyclophosphamide in serum by reversed-Phase high-Performance liquid chromatography.
J. Chromatogr.,
663,
395–399
(1995).
-
Bonadonna, G.,
Valagussa, P.,
Moliterni, A.,
Zambetti, M. and
Brambilla, C.,
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-Positive breast cancer. The results of 20 years of follow-Up.
New Engl. J. Med.,
332,
901–906
(1995).
-
Driessen, O.,
Highley, M. S.,
Harper, P. G.,
Maes, R. A. A. and
De Bruijn, E. A.,
Description of an instrument for separation of red cells from plasma and measurement of red cell volume.
Clin. Biochem.,
27,
195–196
(1994).
-
Gheuens, E.,
Slee, P. H. Th. J. and
De Bruijn, E. A.,
Bioavailability of cyclophosphamide in the CMF regimen.
Onkologie,
13,
203–206
(1990).
-
Momerency, G.,
Van Cauwenberghe, K.,
Slee, P. H. Th. J.,
Van Oosterom, A. T. and
De Bruijn, E. A.,
The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/Mass spectromety.
Biol. Mass Spectrom.,
23,
149–158
(1994).
-
Tjaden, U. R. and
De Bruijn, E. A.,
Chromatographic analysis of anticancer drugs.
J. Chromatogr.,
531,
235–294
(1990).
